Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H13N |
Molecular Weight | 159.2276 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC#C)CC1=CC=CC=C1
InChI
InChIKey=DPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
Molecular Formula | C11H13N |
Molecular Weight | 159.2276 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Eutonyl Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
272 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
The involvement of noradrenaline, 5-hydroxytryptamine and acetylcholine in imipramine-induced seizures in mice. | 1993 Oct 15 |
|
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. | 1994 Jul 11 |
|
GABAergic and dopaminergic systems may be involved in seizures induced by pyrimethamine in mice. | 1994 Oct |
|
Clinical review: immunomodulatory effects of dopamine in general inflammation. | 2004 Dec |
|
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. | 2004 May 25 |
|
IRAK-M regulates chromatin remodeling in lung macrophages during experimental sepsis. | 2010 Jun 16 |
|
Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. | 2010 Nov 1 |
|
Alterations in hippocampal serotonergic and INSR function in streptozotocin induced diabetic rats exposed to stress: neuroprotective role of pyridoxine and Aegle marmelose. | 2010 Sep 25 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3208065
Curator's Comment: The two molecular forms of monoamine oxidase (MAO), MAO-A and MAO-B, were determined quantitatively in discrete regions of the human brain at autopsy, and in cerebral microvessels, choroid plexus and liver samples from the same subjects. MAO was assessed by specific[3H] pargyline binding, which is stoichiometric and irreversible, and by measuring the rate of oxidation of several MAO substrates. Basal ganglia structures (caudate, putamen, globus pallidus and substantia nigra) and hippocampus had about twice the levels of MAO that were present in the cerebral cortex and cerebellum. Cerebral microvessels, which constitute the blood-brain barrier, had minimal MAO, while the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, and the liver had higher MAO levels than any brain region. The vast majority of MAO (80-95%) in these tissues was of the B type, except in microvessels, where total MAO activity was low. Specific [3H]pargyline binding correlated well with the oxidation rates for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and benzylamine in all tissues. Both specific [3H]pargyline binding and the rate of oxidation of MAO substrates increased with age.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:21:34 GMT 2025
by
admin
on
Mon Mar 31 18:21:34 GMT 2025
|
Record UNII |
9MV14S8G3E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C02LL01
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
||
|
WHO-VATC |
QC02LL01
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
||
|
NCI_THESAURUS |
C667
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
||
|
WHO-VATC |
QC02KC01
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
||
|
WHO-ATC |
C02KC01
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01626
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
7262
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
2065
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
DTXSID3023423
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
555-57-7
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
100000082797
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
9MV14S8G3E
Created by
admin on Mon Mar 31 18:21:35 GMT 2025 , Edited by admin on Mon Mar 31 18:21:35 GMT 2025
|
PRIMARY | |||
|
1350
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
D010293
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
209-101-6
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
m8412
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | Merck Index | ||
|
4688
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
7930
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | RxNorm | ||
|
C66322
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
SUB09626MIG
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
PARGYLINE
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY | |||
|
CHEMBL673
Created by
admin on Mon Mar 31 18:21:34 GMT 2025 , Edited by admin on Mon Mar 31 18:21:34 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |